Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:MEK_inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:L01XE25
|
| gptkbp:brand |
gptkb:Mekinist
|
| gptkbp:CASNumber |
871700-17-3
|
| gptkbp:chemicalFormula |
C26H23FIN5O4
|
| gptkbp:combines |
gptkb:dabrafenib
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:discoveredIn |
2010s
|
| gptkbp:halfLife |
4.5 days
|
| gptkbp:inhibitedBy |
gptkb:MAPK/ERK_pathway
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits MEK1 and MEK2
|
| gptkbp:metabolism |
non-CYP enzymes
|
| gptkbp:molecularWeight |
615.4 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:cardiomyopathy
diarrhea fatigue hypertension rash |
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:usedFor |
treatment of melanoma
treatment of non-small cell lung cancer treatment of anaplastic thyroid cancer |
| gptkbp:bfsParent |
gptkb:MAP2K1
gptkb:MAP2K1_gene gptkb:MEK1/2 |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trametinib
|